| 5 | 1/1 | 返回列表 |
| 查看: 3962 | 回復(fù): 16 | ||||
| 當(dāng)前只顯示滿足指定條件的回帖,點(diǎn)擊這里查看本話題的所有回帖 | ||||
wachina至尊木蟲 (知名作家)
|
[交流]
武田fasiglifam (TAK-875)宣告失敗,恒瑞呋格列泛齒亡唇寒 已有16人參與
|
|||
|
Takeda terminates development activities for fasiglifam (TAK-875) Takeda Pharmaceutical Company Limited (Takeda) announced that it has decided voluntarily to terminate the development activities for fasiglifam (TAK-875), an investigational treatment for type 2 diabetes, due to concerns about liver safety. Patient safety is Takeda's highest priority. The company has worked with three independent panels of experts to provide for the safety of trial participants and ensure independent safety oversight for the clinical trials throughout the duration of the fasiglifam (TAK-875) Phase 3 development program. The expert panels include the independent Data Monitoring Committee (DMC), a committee that oversees the fasiglifam global clinical development program, reviews the unblinded clinical data from program trials and provides continual safety oversight of trial subjects and recommendations. The DMC is comprised of clinical experts in endocrinology, cardiology and hepatology as well as a statistician. The independent Liver Safety Evaluation Committee (LSEC) is comprised of five hepatologists with expertise in drug-induced liver injury. While remaining blinded to treatment information, the LSEC regularly evaluates data on liver enzymes elevations and adjudicates cases that impacted the liver. In addition, an independent Executive Committee (EC) provides additional oversight for the fasiglifam (TAK-875) cardiovascular outcomes trial. After careful consideration of the data emerging from all the clinical trials and in consultation with these panels, the company has reached the conclusion that, on balance, the benefits of treating patients with fasiglifam (TAK-875) do not outweigh the potential risks. For this reason, Takeda has decided voluntarily to terminate the development activities for fasiglifam. 作為慢性疾病:糖尿病的治療,肝毒性太致命了,難怪武田揮淚斬馬謖。值得一提的是,恒瑞也向CFDA申報(bào)了GPR-40激動(dòng)劑呋格列泛,現(xiàn)在心里估計(jì)也是拔涼拔涼的 |
新藥仿藥 |
銅蟲 (小有名氣)
木蟲 (著名寫手)
鐵蟲 (初入文壇)
| 哎。。。。。! |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 生物學(xué)調(diào)劑招人。! +3 | 山海天嵐 2026-03-17 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 0703化學(xué)調(diào)劑 ,六級(jí)已過(guò),有科研經(jīng)歷 +12 | 曦熙兮 2026-03-15 | 12/600 |
|
|
[考研]
|
.6lL 2026-03-18 | 6/300 |
|
|
[考研] 一志愿西安交通大學(xué)材料工程專業(yè) 282分求調(diào)劑 +5 | 楓橋ZL 2026-03-18 | 7/350 |
|
|
[考研] 346求調(diào)劑[0856] +3 | WayneLim327 2026-03-16 | 6/300 |
|
|
[考研] 0703化學(xué)調(diào)劑,求各位老師收留 +10 | 秋有木北 2026-03-14 | 10/500 |
|
|
[考研] 085601專碩,總分342求調(diào)劑,地區(qū)不限 +5 | share_joy 2026-03-16 | 5/250 |
|
|
[考研]
|
胡辣湯放糖 2026-03-15 | 6/300 |
|
|
[考研] 299求調(diào)劑 +5 | △小透明* 2026-03-17 | 5/250 |
|
|
[考研] 0703化學(xué)調(diào)劑 +3 | 妮妮ninicgb 2026-03-17 | 3/150 |
|
|
[考研] 278求調(diào)劑 +5 | 煙火先于春 2026-03-17 | 5/250 |
|
|
[考研] 332求調(diào)劑 +6 | Zz版 2026-03-13 | 6/300 |
|
|
[考研] 275求調(diào)劑 +4 | 太陽(yáng)花天天開心 2026-03-16 | 4/200 |
|
|
[考研] 考研調(diào)劑 +3 | 淇ya_~ 2026-03-17 | 5/250 |
|
|
[考研] 333求調(diào)劑 +3 | 文思客 2026-03-16 | 7/350 |
|
|
[考研] 求老師收留調(diào)劑 +4 | jiang姜66 2026-03-14 | 5/250 |
|
|
[考研] 288求調(diào)劑 +4 | 奇點(diǎn)0314 2026-03-14 | 4/200 |
|
|
[考研] 中科大材料專碩319求調(diào)劑 +3 | 孟鑫材料 2026-03-13 | 3/150 |
|
|
[考研] 297求調(diào)劑 +4 | 學(xué)海漂泊 2026-03-13 | 4/200 |
|
|
[考研] 266求調(diào)劑 +4 | 學(xué)員97LZgn 2026-03-13 | 4/200 |
|